Target intelligence / Profile preview

Synaptic vesicle exocytosis machinery

Molecular classification
Other (Multiprotein machine/complex), SNARE protein, Calcium sensor, SM protein, SNARE chaperones
01

Overview

The synaptic vesicle exocytosis machinery is an essential, highly conserved set of proteins that mediates the fusion of synaptic vesicles with the presynaptic plasma membrane in response to calcium entry, enabling neurotransmitter release at synapses. The core machinery includes SNARE proteins (synaptobrevin/VAMP, syntaxin, SNAP-25), the calcium sensor synaptotagmin, SM proteins (Munc18), and accessory regulators (complexin, Munc13). Dysregulation or poisoning of these proteins impairs neurotransmission, leading to neurological disease or paralysis. This target is not a single molecular entity, but a functional and mechanistic description of a multiprotein system. For structured drug discovery or therapeutic purposes, canonical targets within the machinery are individual proteins (e.g., “Synaptobrevin-2,” “SNAP-25,” “Synaptotagmin-1”). The category “synaptic vesicle exocytosis machinery” should not be used as a canonical drug target in most structured databases.

Other names
Neurotransmitter release apparatussynaptic vesicle fusion complex
02

Mechanism of action

Blockade of SNARE complex assembly (by neurotoxins such as botulinum and tetanus toxins, via proteolytic cleavage of SNARE proteins); Modulation of vesicle priming or fusion (in experimental tool drug/discovery literature)

03

Biological functions

Neurotransmitter releaseSynaptic transmissionCalcium-dependent exocytosis
04

Disease associations

Neurodegenerative disease (dysfunction in these proteins implicated in diseases like Parkinson’s and Alzheimer’s)Neurodevelopmental disorders (e.g., some epilepsies, autism spectrum disorders)Tetanus and botulinum poisoning (neurotoxins block exocytosis machinery)
05

Safety considerations

Disruption of the machinery—either by toxins or genetic mutation—leads to loss of neurotransmitter release, paralysis, or neurological dysfunctionTherapeutic targeting poses risks of wide-ranging CNS effects, including paralysis or seizures
06

Interacting drugs

Botulinum neurotoxins

1 more in the full profile.

Beyond the preview

Go deeper on Synaptic vesicle exocytosis machinery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptic vesicle exocytosis machinery.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call